MRI-based sector analysis enhances prostate palladium-103 brachytherapy quality assurance in a phase II prospective trial of men with intermediate-risk localized prostate cancer - Abstract

PURPOSE: Palladium-103 (103Pd) may be superior to other isotopes in brachytherapy for localized intermediate-risk prostate cancer because of its relatively short half-life, higher initial dose rate, and greater dose heterogeneity within the target volume; these properties also underscore the need for accurate target delineation and postimplant quality assurance.

We assessed the use of prostate sector analysis based on MRI for quality assurance after 103Pd monotherapy.

METHODS AND MATERIALS: Fifty men with intermediate-risk prostate cancer underwent 103Pd monotherapy in a prospective phase II trial at MD Anderson Cancer Center. Dosimetric analyses on day 30 after the implant were done using both CT and fused CT/MRI scans. Dosimetric variables were assessed for the entire prostate and for each of three or six sectors. Volumes and dosimetric variables were compared with paired t tests.

RESULTS: Postimplant dosimetric variables for the entire prostate were significantly different on CT vs. CT/MRI (p = 0.019 for V100 and p < 0.01 for D90). Prostate volumes were smaller on the CT/MRI scans (p < 0.00001). The base sector contributed the greatest difference, with doses based on CT/MRI lower than those based on CT (p < 0.01 for V100 and D90). To date, these lower base doses have not affected biochemical outcomes for patients with disease in prostate base biopsy samples.

CONCLUSIONS: CT/MRI is more precise than CT for prostate volume delineation and dosimetric quality assessment and thus provides superior heterogeneity control assessment after 103Pd monotherapy implants.

Written by:
Takiar V, Pugh TJ, Swanson D, Kudchadker RJ, Bruno TL, McAvoy S, Mahmood U, Frank SJ.   Are you the author?
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

Reference: Brachytherapy. 2013 May 11. pii: S1538-4721(13)00244-4.
doi: 10.1016/j.brachy.2013.04.001


PubMed Abstract
PMID: 23669149

UroToday.com Prostate Cancer Section